The estimated Net Worth of Simon H Stertzer is at least $1.82 millió dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,746,319 and over the last 8 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.
Simon has made over 15 trades of the BioCardia stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 166,666 units of BCDA stock worth $999,996 on 5 July 2019.
The largest trade he's ever made was buying 3,333,332 units of BioCardia stock on 24 December 2018 worth over $2,499,999. On average, Simon trades about 212,200 units every 54 days since 2016. As of 5 July 2019 he still owns at least 642,029 units of BioCardia stock.
You can see the complete history of Simon Stertzer stock trades at the bottom of the page.
Dr. Simon H. Stertzer M.D. serves as Independent Chairman of the Board of the Company. Dr. Stertzer is a Professor of Medicine, Emeritus at the Stanford University School of Medicine, Division of Cardiovascular Medicine. He was appointed Professor of Medicine at Stanford University in 1998, and became Professor Emeritus at Stanford University in 2011. Dr. Stertzer serves on the medical advisory board of Avenda Health, a private prostate cancer therapy company, and was appointed in June 2019. Dr. Stertzer is managing member of Windrock Enterprises, LLC, a real estate investment company, since May 1999. He has served as a Director of Frontiere Algorithmic Design LLC, a software development company, from June, 2014. Dr. Stertzer was a founder and board member of Arterial Vascular Engineering, an angioplasty balloon and stent company that went public in 1996 and was subsequently acquired by Medtronic. He also serves as Director of AVIA App LLC since 2015. Dr. Stertzer received his Doctor of Medicine degree from New York University. He also earned a Certificat de Physiologie from University of Paris (Sorbonne) and had a fellowship at New York University Hospital in Cardiovascular Disease. Dr. Stertzer received a Bachelor of Arts degree in Humanities from Union College.
As the Independent Chairman of the Board of BioCardia, the total compensation of Simon Stertzer at BioCardia is $76,250. There are 7 executives at BioCardia getting paid more, with Peter Altman having the highest compensation of $677,501.
Simon Stertzer is 83, he's been the Independent Chairman of the Board of BioCardia since 2002. There are no older and 14 younger executives at BioCardia.
Simon's mailing address filed with the SEC is 125 Shoreway Rd, San Carlos, CA 94070, USA.
Over the last 8 years, insiders at BioCardia have traded over $2,555,815 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer és Richard M Krasno. On average, BioCardia executives and independent directors trade stock every 48 days with the average trade being worth of $1,321,186. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 19 January 2024, trading 129,802 units of BCDA stock currently worth $55,815.
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
BioCardia executives and other stock owners filed with the SEC include: